Significance of CTLA-4 and CD14 genetic polymorphisms in clinical outcome after allogeneic stem cell transplantation [3]

Bone Marrow Transplantation

Volumn 40, Issue 10, 2007, Pages 1001-1002

  Vannucchi, A M ^a   Guidi, S ^a   Guglielmelli, P ^a   Glinz, S ^a   Lombardini, L ^a   Busca, A ^b   Locatelli, F ^b   Dall'Omo, A M ^b   Bosi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GUANINE; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; THYMINE; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 4;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DONOR; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAFT SURVIVAL; HAPLOTYPE; HLA MATCHING; HUMAN; INNATE IMMUNITY; LETTER; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MONOCYTE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME;

ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; POLYMORPHISM, GENETIC; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 35748940287     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705850     Document Type: Letter

References (10)

1. Petersdorf EW, Mälkki M. Genetics of risk factors for graft-versus-host disease. Semin Hematol 2006; 43: 11-23.
2. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host-disease. Semin Hematol 2006; 43: 3-10.
3. Snanoudj R, de Preneuf H, Creput H, Arzouk C, Deroure N, Beaudreuil B et al. Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 2007; 19: 693-704.
4. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506-511.
5. Perez-Garcia A, De la Camara R, Roman-Gomez J, Jimenez-Velasco A, Encuentra M, Nieto JB et al. CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors. Blood 2007; 110: 461-467.
6. Triantafilou M, Triantafilou K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol 2002; 23 301-304.
7. Gregory CD. CD14-dependent clearance of apoptotic cells: Relevance to the immune system. Curr Opin Immunol 2000; 12: 27-34.
8. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD et al. A polymorphism in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976-983.
9. Palmer SM, Klimecki W, Yu L, Reinsmoen NL, Snyder LD, Ganous TB et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007; 7: 693-699.
10. Heesen M, Kunz D, Rossaint R, Blomeke B. Real-time PCR assay with fluorescent hybridization probes for rapid genotyping of the CD14 promotor polymorphism. Clin Chem 2000; 46: 1866-1877.